BTIG Maintains Buy on AtriCure, Raises Price Target to $63
BTIG analyst Ryan Zimmerman maintains AtriCure (NASDAQ:ATRC) with a Buy and raises the price target from $55 to $63.
Stocks · News reference
Salesforce To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Cantor Fitzgerald raised
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Abbott To Rally Over 31%? Here Are 10 Top Analyst Forecasts For Friday
Analysts raised targets for ACN, SYNA, ATRC and MPC; cut targets for CSX, NKE, MKC and FHTX, with ATRC downgraded to Hold.
This AST SpaceMobile Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Analysts downgraded FHTX, BUSE, ASTS, ATRC and EQBK; targets fell for BUSE, ASTS and EQBK but rose for ATRC.
Freedom Capital Markets Downgrades AtriCure to Hold, Raises Price Target to $57
'Diesel falls sharply as EU considers releasing 50mn barrels under pressure from Trump; Trump has asked Europe to release at least 100mn barrels of diesel to the markets' - FT Exclusive
https://www.ft.com/content/97200b07-755c-40ce-a50b-b51666bd4b7e?syn-25a6b1a6=1
Deutsche Bank Initiates Coverage On Columbia Banking System with Hold Rating, Announces Price Target of $32
Deutsche Bank analyst Bernard von-Gizycki initiates coverage on Columbia Banking System (NASDAQ:COLB) with a Hold rating and announces Price Target of $32.